U.S. Markets closed

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0200-0.0600 (-5.56%)
At close: 4:00PM EDT
1.0100 -0.01 (-0.98%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0800
Open1.0205
Bid1.0000 x 1000
Ask1.0100 x 1100
Day's Range1.0000 - 1.0300
52 Week Range0.8500 - 2.8000
Volume733,518
Avg. Volume1,812,374
Market Cap40.88M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.4040
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
  • Benzinga

    Soligenix To Test Synthetic Hypericin In Psoriasis Patients

    Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Related Content: Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate. Visible light-activated synthetic hypericin is a photodynamic therapy (PDT) that is expected to avoid much of the long-term risks associated with other PDT treatments. Synthetic hypericin is a potent phot

  • PR Newswire

    Soligenix to Advance Synthetic Hypericin Development in Psoriasis

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Pha

  • Newsfile

    Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics

    Soligenix discusses its contribution to addressing future serious public health threats in a podcast New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has already cost the United States an estimated $16 trillion in lost economic output, and has resulted in the loss of over 600,000 lives. At the end of last month, the country reached the dubious milestone of 39 million diagnosed cases of COVID, however, researchers ...